Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII.
- 1 August 1977
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 30 (8) , 770-773
- https://doi.org/10.1136/jcp.30.8.770
Abstract
A patient is described who had an inhibitor to coagulation factor XIII associated with serum autoantibodies to certain tissues. The relationship of these abnormal findings to practolol therapy suggests that this was practolol-induced lupus erythematosus. Further investigations delineating the site of action of the inhibitor to factor XIII are reported.This publication has 19 references indexed in Scilit:
- Untoward effects associated with practolol administration: oculomucocutaneous syndrome.BMJ, 1975
- SCLEROSING PERITONITIS, AN UNUSUAL REACTION TO A β-ADRENERGIC-BLOCKING DRUG (PRACTOLOL)The Lancet, 1974
- A New Haemorrhagic Disorder with Defective Fibrin Stabilization and CryofibrinogenaemiaBritish Journal of Haematology, 1974
- Systemic Lupus Erythematosus Syndrome Induced by PractololBMJ, 1973
- Haemorrhagic Syndrome of Autoimmune Origin with a Specific Inhibitor against Fibrin Stabilizing Factor (Factor XIII)*British Journal of Haematology, 1972
- Circulating anticoagulants to factor VIII: Immunochemical studies and clinical response to factor VIII concentratesThe American Journal of Medicine, 1970
- An Inhibitor to Fibrin Stabilizing Factor (FSF, Factor XIII)Scandinavian Journal of Haematology, 1970
- Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporationJournal of Clinical Investigation, 1969
- A pathological inhibitor of fibrin cross-linkingJournal of Clinical Investigation, 1968
- CIRCULATING ANTICOAGULANTSMedicine, 1961